Crescentis Capital rights issue: board targets ₹80cr in 2026

What changed and why the board meeting moved

Crescentis Capital Limited has rescheduled its Board of Directors meeting from September 29, 2026 to September 30, 2026. The company said the shift was due to “unavoidable circumstances”, according to a filing made to BSE Limited on September 28, 2026. While the date moved by a day, the core agenda remained the same. The board meeting is meant to review updates and progress on a proposed fund-raising exercise. The proposed route is a rights issue of equity shares. For investors, the rescheduling itself is not the main event, but it signals that the company is continuing the formal process around the rights issue. The next set of disclosures are expected to focus on how far the internal approvals and preparatory steps have progressed.

The primary agenda: reviewing the proposed rights issue

The company has indicated that the board intends to examine the status of the rights issue proposal, as permitted under applicable law. The discussion is expected to cover the work undertaken to date to move the proposal forward. Crescentis Capital has already communicated that it is exploring raising funds via equity shares on a rights basis. A rights issue typically offers existing shareholders the option to subscribe to new shares in proportion to their holdings. In this case, the company has previously disclosed that the fund raise could be up to ₹80 crore. However, key operational details such as the issue price and entitlement ratio have not been announced in the provided information. The company has also stated that the record date for the rights issue will be announced later.

Role of the Fund Raising Committee formed in May 2026

A key part of the September 30 meeting is expected to be a review of the Fund Raising Committee’s progress. Crescentis Capital constituted this committee during the board meeting held on May 29, 2026. The committee’s mandate includes evaluating the proposal to raise funds through rights issues, subject to regulatory and statutory approvals. The board meeting agenda, as described, includes reviewing the progress made by the committee since May. It also includes evaluating the regulatory and statutory approvals required for the transaction. Another item is considering the proposal for raising funds by issuing equity shares on a rights basis. This structure indicates that the rights issue is still moving through preparatory and compliance stages rather than being at a final pricing or timeline stage.

The ₹80 crore fund-raise plan and issue structure

In earlier board actions referenced in the provided context, Crescentis Capital approved raising up to ₹80 crore through a rights issue of fully paid-up equity shares. The disclosures referenced also state that the rights issue would involve fully paid-up equity shares of face value ₹10 each. The issue would be offered to eligible equity shareholders on a rights basis. The company has stated that the Fund Raising Committee will finalize key terms, including the rights entitlement ratio and issue price. Until these terms are disclosed, investors typically focus on the maximum size, the stated purpose (fund raising), and the process milestones. The board’s continued review suggests the company is aligning the transaction with SEBI regulations and listing disclosure requirements.

Financial snapshot: FY26 loss and revenue numbers disclosed

The provided information includes audited financial references for FY26 and Q4 FY26. Crescentis Capital’s board approved FY26 audited financials reporting a net loss of ₹2.53 crore for the year and a net loss of ₹7.35 crore for Q4 FY26. Separately, another line in the provided text states the company reported a net loss of ₹7.35 crore for the financial year ended March 31, 2026. The same body of information also states the company reported a narrowed net loss of ₹2.5263 crore for FY26 compared with a loss of ₹5.4224 crore in FY25, with total revenue from operations at ₹1.4838 crore in FY26. These figures, taken as presented, indicate that the company has communicated multiple loss numbers in the surrounding updates, including a quarterly loss figure and an annual loss figure. Investors generally track which figure is linked to the audited annual statement versus quarterly results in the company’s formal filings.

Prior shareholder approvals and governance trail

Crescentis Capital said shareholders approved all five resolutions at its 33rd Annual General Meeting held on August 26, 2026. While the specific resolutions are not detailed in the provided text, the approval of multiple resolutions indicates that the company has been using formal governance channels through 2026. The company also referenced that it had earlier planned a board meeting on September 29, 2026 to consider updates on the proposed equity rights issue fund raising. The sequence of AGM approvals and board-level reviews is relevant because rights issues require layered approvals and compliance steps. In the current update, the company’s focus appears to be on progress tracking rather than final launch parameters.

Track record: the July 2025 rights issue

Crescentis Capital has also cited a successfully concluded rights issue in July 2025. In that transaction, the company raised ₹49.0391 crore through the issuance of 70,05,579 equity shares at ₹70 per share. The “Crescentis Capital Ltd Rights” table in the provided content also refers to a rights issue ratio of 7:10, with face value ₹10, and a premium of ₹60, with an announcement date of November 5, 2024 and a record date and ex-rights date of June 6, 2025. This historical data provides a reference point for how the company has structured a rights issue in the recent past. It also shows that Crescentis Capital has experience executing a rights issue within the listed market framework.

Timeline of key disclosed events

The following timeline compiles the dated events mentioned in the provided context.

Key numbers disclosed so far

This table consolidates the figures explicitly mentioned, converted to a single unit of ₹ crore.

Market impact and what investors will watch next

The immediate market relevance of the September 30 board meeting is tied to process clarity. The company has already disclosed the maximum fund-raising amount and the intended route, but not the commercial terms. For existing shareholders, the eventual entitlement ratio and issue price will shape participation decisions, and these remain to be finalized by the committee. Another near-term item to monitor is the record date, which the company has said will be announced later. Any subsequent filing that sets out the timetable, price, and ratio will be central to how the market assesses dilution and capital inflow. Separately, investors will also track how the company reconciles and presents the FY26 loss numbers across different updates in its final, audited disclosures.

Conclusion

Crescentis Capital’s board has moved its rights issue review meeting to September 30, 2026, keeping the agenda focused on progress toward a proposed ₹80 crore equity rights issue. The next milestones, based on the company’s stated process, include finalizing the entitlement ratio and issue price through the Fund Raising Committee and announcing the record date through formal stock exchange disclosures.